VRTX Stock Recent News

Vertex Pharmaceuticals is unusually resilient for a biotech stock. The company has spectacular growth prospects with multiple promising late-stage programs.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Cantor Global Healthcare Conference September 17, 2024 9:10 AM ET Company Participants Susie Lisa - SVP, IR Manisha Pai - Executive Director, IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Olivia Brayer Joining us this morning at our Cantor Global Healthcare Conference. Really excited to have another year of it.

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.

VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Morgan Stanley Conference Call September 5, 2024 11:30 AM ET Company Participants Reshma Kewalramani - President and CEO Charlie Wagner - CFO Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley.

Vertex enjoys a monopoly that could soon grow stronger. The company could have multiple potential blockbuster drugs on the way.

MENLO PARK, Calif.--(BUSINESS WIRE)-- #FDA--FDA approves U.S. pivotal trial of Jupiter Endovascular pulmonary embolism system with Endoportal Control technology.

Vertex Pharmaceuticals is different from Novo Nordisk in several ways. The two companies could compete against each other in the future.

Vertex's (VRTX) CF sales are expected to remain strong despite a slight slowdown in the growth rate. Casgevy and suzetrigine (if approved) are set to provide the necessary diversification from the CF franchise.

Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.